Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women

Human Reproduction

Volumn 21, Issue 10, 2006, Pages 2715-2720

  Ho, Jason Yen Ping ^a,b,e   Chen, Ming Jer ^a,c   Sheu, Wayne Huey Herng ^a,b,d   Yi, Yu Chiao ^a,d   Tsai, Andy Chi Wei ^a   Guu, Hwa Fen ^a   Ho, Esther Shih Chu ^a,d  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^e CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

Atherosclerotic vascular disease; C reactive protein; Estrogen; Homocysteine; Vasodilation

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CONJUGATED ESTROGEN; ESTRADIOL; FIBRINOGEN; HOMOCYSTEINE; LIPID;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL FUNCTION; BRACHIAL ARTERY; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; FEMALE; FIBRINOGEN BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; LIPID BLOOD LEVEL; POSTMENOPAUSE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; TREATMENT DURATION; VASCULAR ENDOTHELIUM; VASODILATATION;

EQUIDAE;

EID: 33749593535     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/del245     Document Type: Article

References (36)

1. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291,1701-1712.
2. van Daal WM, Smolders RG, van der Mooren MJ, Teerlink T and Kenemans P (1999) Hormone replacement therapy and plasma homocysteine levels. Obstet Gynecol 94,485-491.
3. Barnes JF, Farish E, Rankin M and Hart DM (2005) Effects of two continuous hormone therapy regimens on C-reactive protein and homocysteine. Menopause 12,92-98.
4. Bruschi F, Dal Pino D, Fiore V, Parazzini F, Di Pace R, Cesana BM, Melotti D and Crosignani PG (2004) Effect of oral or transdermal hormone replacement therapy on homocysteine levels: A randomized clinical trial. Maturitas 48,33-38.
5. Bukowska H, Stanosz S, Zochowska E, Millo B, Sieja K, Chelstowski K and Naruszewicz M (2005) Does the type of hormone replacement therapy affect lipoprotein (a), homocysteine, and C-reactive protein levels in postmenopausal women? Metabolism 54,72-78.
6. Castelli WP (1984) Epidemiology of coronary heart disease: The Framingham study. Am J Med 76,4-12.
7. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK and Deanfield JE (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340,1111-1115.
8. Celermajer DS, Sorensen KE, Bull C, Robinson J and Deanfield JE (1994) Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 24,1468-1474.
9. Davison S and Davis SR (2003) New markers for cardiovascular disease risk in women: Impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 88,2470-2478.
10. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GH, Sheahan RG, Israelsson B et al. (1997) Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 277,1775-1781.
11. Hackam DG and Anand SS (2003) Emerging risk factors for atherosclerotic vascular disease: A critical review of the evidence. JAMA 290,932-940.
12. Ho JY, Guu HF, Yi YC, Chen MJ and Ho ES (2005) The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is inversely correlated with a mature oocyte yield and can predict 'low responders'. Fertil Steril 83,883-888.
13. Hsu HY, Chen YT, Sheu WH, Sheng WY and Chao AC (2002) Comparison of brachial artery flow-mediated vasodilatation in symptomatic and asymptomatic patients with carotid arterial stenosis. Am J Cardiol 90,814-816.
14. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B and Vittinghoff E (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) research group. JAMA 280,605-613.
15. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C and Luscher TF (1995) Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 91,1314-1319.
16. Kannel WB, Wolf PA, Castelli WP and D'Agostino RB (1987) Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 258,1183-1186.
17. Kelemen LE, Anand SS, Hegele RA, Stampfer MJ, Rosner B, Willett WC, Montague PA, Lonn E, Vuksan V, Teo KK et al. (2004) Associations of plasma homocysteine and the methylenetetrahydrofolate reductase C677T polymorphism with carotid intima media thickness among South Asian, Chinese and European Canadians. Atherosclerosis 176,361-370.
18. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, Yeung AC and Creager MA (1994) Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 121,936-941.
19. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW and Ganz P (1986) Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 315,1046-1051.
20. de Maat MP, Pietersma A, Kofflard M, Sluiter W and Kluft C (1996) Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. Atherosclerosis 121,185-191.
21. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R et al. (2003) Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349,523-534.
22. Maresca G, Di Blasio A, Marchioli R and Di Minno G (1999) Measuring plasma fibrinogen to predict stroke and myocardial infarction: An update. Arterioscler Thromb Vasc Biol 19,1368-1377.
23. Mijatovic V, Netelenbos C, van der Mooren MJ, de Valk-de Roo GW, Jakobs C and Kenemans P (1998) Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women. Fertil Steril 70,1085-1089.
24. Neumeuli T, Katzenschlager R, Hassan A, Klaar U, Schwarzacher S, Giogar D, Bauer P and Weidinger F (1997) Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis 129,111-118.
25. Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, Wallace RB, Jackson RD, Pettinger MB and Ridker PM (2002) Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: Prospective analysis from the Women's Health Initiative observational study. JAMA 288,980-987.
26. Ridker PM, Cushman M, Stampfer MJ, Tracy RP and Hennekens CH (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336,973-979.
27. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288,321-333.
28. Sheu WH, Juang BL, Chen YT and Lee WJ (1999) Endothelial dysfunction is not reversed by simvastatin treatment in type 2 diabetic patients with hypercholesterolemia. Diabetes Care 22,1224-1225.
29. Smolders RG, van der Mooren MJ, Teerlink T, Merkus JM, Kroeks MV, Franke HR, Stehouwer CD and Kenemans P (2003) A randomized placebo-controlled study of the effect of transdermal vs. oral estradiol with or without gestodene on homocysteine levels. Fertil Steril 79,261-267.
30. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Hamsten A, Taskinen MR and Yki-Jarvinen H (2001) Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 85,619-625.
31. Vongpatanasin W, Tuncel M, Wang Z, Arbique D, Mehrad B and Jialal I (2003) Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am Coll Cardiol 41,1358-1363.
32. Wakatsuki A, Ikenoue N, Shinohara K, Watanabe K and Fukaya T (2004) Effect of lower dosage of oral conjugated equine estrogen on inflammatory markers and endothelial function in healthy postmenopausal women. Arterioscler Thromb Vasc Biol 24,571-576.
33. Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DA and Anderson PW (2000) The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A randomized, controlled trial. J Clin Endocrinol Metab 85,214-218.
34. Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG and Moncada S (1994) Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci USA 91,5212-5216.
35. Wenger NK, Speroff L and Packard B (1993) Cardiovascular health and disease in women. N Engl J Med 329,247-256.
36. Zegura B, Keber I, Sebestjen M and Koenig W (2003) Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis. Atherosclerosis 168,123-129.